<DOC>
	<DOC>NCT01195038</DOC>
	<brief_summary>The study is designed to assess the immunogenicity and safety of one booster vaccination with 45 Î¼g of a recombinant H5N1 influenza (A/Indonesia/05/2005) HA vaccine in healthy young adults, previously primed with a two-vaccination of 3 different doses of a recombinant H5N1 influenza (A/Vietnam/1203/2004) HA vaccine in a priming study (JPIP501-01a, NCT00980447).</brief_summary>
	<brief_title>Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Influenza in Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects who completed a priming study (JPIP50101a, NCT00980447) Male and female healthy adults Written informed consent obtained from the subject before study entry History of H5N1 influenza or vaccination of other H5N1 influenza vaccines Clinically diagnosed cardiovascular, hematological, psychological, neurological, hepatic, renal, pulmonary (including asthma), endocrinological or gastrointestinal disorder Confirmed immune deficiency conditions, or diagnosed autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus Severe allergic reactions or anaphylaxis to foods or drugs (including vaccines) Treatment with disallowed drugs including other study drugs Pregnant or nursing (lactating) women Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>41 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Avian influenza, H5N1, pandemic, recombinant HA vaccine</keyword>
</DOC>